Drug Shortages in Health Care Institutions: Perspectives in Early 2012

Drug Shortages in Health Care Institutions: Perspectives in Early 2012


Géraldine Ottino , Research Assistant , Denis Lebel , BPharm, MSc, FCSHP , Assistant Director , Jean-François Bussières , BPharm, MSc, FCSHP , Director

In news articles published in the Canadian Medical Association Journal in 2010 and 2011, Eggertson highlighted the problem of drug shortages in Canada and described initiatives of the Canadian Pharmacists Association, hospital pharmacists, and drug manufacturers to address the problem.1,2

Many stakeholders have underscored the importance of the drug shortage problem and its risks, but few quantitative data have been published.3,4 A few regulatory agencies (e.g., the US Food and Drug Administration5 and the Agence française de sécurité sanitaire des produits de santé in France6) and a few professional organizations and associations (e.g., the US Institute for Safe Medication Practices,7 the American Society of Health-System Pharmacists,8 and the Canadian Pharmacists Association9) have published online guidelines and lists of product shortages to make it easier to manage these events.

In Canada, the Pharmacy Practice Research Unit of the Centre hospitalier universitaire Sainte-Justine launched an open-access website in February 2011 that provides a progress report on all drug shortages in health care institutions (see www.fridaypm.ca [English] and www.vendredipm.ca [French]). Many of these shortages also affect outpatients using oral formulations. Initially, the website was being updated every 2 weeks by our research team using a list of drug shortages provided by the wholesaler McKesson Canada, under contract to SigmaSanté (the group purchasing agent for hospital group purchases in the Montréal and Laval areas and the Eastern Townships of Quebec) and through self-reporting by hospitals. Starting in January 2012, the website was being updated directly by the manufacturers on a voluntary pilot basis; doing so became mandatory on April 1, 2012, according to contractual terms and conditions with SigmaSanté. This real-time updating should make it possible to immediately display progress reports for all of the stakeholders.

Our research unit has been interested in drug shortages for more than a year. In a recently published retrospective study,10 we compiled a list of all the drug shortages experienced by health care institutions in the Montréal and Laval areas and the Eastern Townships from January 2006 to August 2010. Since then, we have gathered data on shortages from August 30, 2010, to August 23, 2011. Our latest data indicate that there were a total of 429 drug shortages in this 12-month period in 2010–2011; the corresponding numbers of drug shortages were 493 in calendar year 2006, 400 in 2007, 442 in 2008, 680 in 2009, and 385 in the first 8 months of 2010. The average duration (± standard deviation) of the drug shortages has remained similar, with 108 ± 130 days (range 5–1623 days) over the period 2006–2010 and 103 ± 85 days (range 8–363) for the 12-month period in 2010–2011.

The number of manufacturers involved in drug shortages has declined (41 in 2010–2011 versus 70 over the period 2006–2010), undoubtedly because of mergers and integration or closing of certain drug manufacturers. Most of the documented shortages came from generic drug manufacturers, and their relative ranking has remained similar. For the period 2006–2010, the ranking for generic manufacturers, in decreasing order, was as follows: Apotex, accounting for 19% of total drug shortages; Pharmascience, 14%; Novopharm (now Teva), 12%; Sandoz, 10%; Hospira, 6%; Teva, 4%; Baxter, 3%; Ratiopharm, 3%; Omega, 2%; and Taro, 2%. For the 12-month period in 2010–2011, the ranking was Teva, 23%; Apotex, 16%; Pharmascience, 12%; Hospira, 7%; Sandoz, 7%; Baxter, 5%; AA Pharma (created from the resale of certain licences held by Apotex), 3%; Schering, 3%; Abbott, 3%; and Merck Canada, 2%.

In both periods, most therapeutic classes were involved in drug shortages. For the 12-month study period in 2010–2011, drug classes involved in shortages were, in decreasing order, central nervous system agents (AHFS drug classification 28:00), accounting for 24% of products; anti-infective agents (08:00), 16%; cardiovascular drugs (24:00), 10%; antineoplastic drugs (10:00), 7%; electrolytic, caloric, and water balance agents (40:00), 7%; gastrointestinal drugs (56:00), 7%; hormones and synthetic substitutes (68:00), 7%; and all other classes, 22%.

Our work underlines the need to document the quantities and impacts of drug shortages. The actual status of drug shortages by product should be updated daily by manufacturers and published online, as this information is essential to efficiently manage drug shortages and reduce delays in the availability of relevant information to all stakeholders. The website set up by our team and the contractual framework to be used by our group purchasing organization may be of assistance in obtaining manufacturers’ data about shortages. Finally, there is no doubt that collaboration among patients, physicians, and pharmacists will be required to react proactively in the event of drug shortages.

References

1  Eggertson L. Continuing drug shortages affect North American patients. CMAJ 2010;182(18):E811–E812.
cross-ref  pubmed  pmc  

2  Eggertson L. Drug shortage registry under discussion. CMAJ 2011; 183(10):E637–E638.
cross-ref  pubmed  pmc  

3  Traynor K. Drug shortages mount in 2010. Am J Health Syst Pharm 2010; 67(18):1492–1494.
cross-ref  pubmed  

4  Canadian drug shortages survey: final report. Ottawa (ON): Canadian Pharmacists Association; 2010 Dec [cited 2012 Mar 21]. Available from: www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/DrugShortagesReport.pdf

5  Drug shortages. Silver Spring (MD): US Food and Drug Administration; [cited 2011 Jun 14]. Available from: www.fda.gov/Drugs/DrugSafety/DrugShortages/default.htm

6  Formulaire de déclaration de rupture de stocks à l’intention des laboratoires. Saint Denis (France): Agence française de sécurité sanitaire des produits de santé; 2008 [cited 2011 Jun 14]. Available from: www.afssaps.fr/Infos-de-securite/Ruptures-de-stock-et-arrets-de-commercialisation-des-medicaments
pubmed  pmc  

7  Drug shortages: national survey reveals high level of frustration, low level of safety. Horsham (PA): Institute for Safe Medication Practices; 2010 Sep 23 [cited 2011 Jun 14]. Available from: www.ismp.org/Newsletters/acutecare/articles/20100923.asp

8  ASHP Expert Panel on Drug Product Shortages, Fox ER, Birt A, James KB, Kokko H, Salverson S, Soflin DL. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm 2009;66(15):1399–1406.
cross-ref  pubmed  

9  Drug shortages: a guide for assessment and patient management. Ottawa (ON): Canadian Pharmacists Association; 2010 [cited 2012 Mar 21]. Available from: www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/DrugShortagesGuide.pdf

10  Bussières JF, Chiveri A, Lebel D. Perspective sur les ruptures d’approvision-nement de médicaments en établissement de santé de 2006 à 2010. Can J Hosp Pharm 2011;64(6):426–435.


Pharmacy Practice Research Unit, CHU Sainte-Justine, Montréal, Quebec

Géraldine Ottino is also a DPharm student at Université Claude Bernard Lyon 1, Villeurbanne, France. Denis Lebel is also Assistant Director, Pharmaceutical Care, Teaching, and Research, with the Pharmacy Department of CHU Sainte-Justine. Jean-François Bussières is also Director of the Pharmacy Department of CHU Sainte-Justine and Professor with the Faculty of Pharmacy, Université de Montréal. ( Return to Text )

(Return to Top)



Canadian Journal of Hospital Pharmacy , VOLUME 65 , NUMBER 2 , March-April 2012



ISSN 1920-2903 (Online)
Copyright © 2019 Canadian Society of Hospital Pharmacists